Skewed X-Inactivation
Project for Advanced Genetics, Fall 2012 Visual Teaching Aid Audrey Squire Erica Schindewolf No Copyright infringement intended Pictures and music taken from the internetFrom:aud712Views:8 1ratingsTime:03:38More inEducation

Read the original post:
Skewed X-Inactivation - Video

Recommendation and review posted by Bethany Smith

Dabs for farmer + Next Seeds...more importantly READ DESCRIPTION
Farmer is my friend and asked me to let you guys know about this situation since he is not able to let youtube know. Here is a link to Farmer #39;s facebook page where you can watch a video made by him regarding the situation. http://www.facebook.com Here is a link to Northwest Leaf. http://www.facebook.com Let them know what you think of the situation if it #39;s affecting you or the people you care about. They are making low blows now regardless of what has gone down since school of dank. From an outsiders point of view, Not the most professional way to handle this situation. It #39;s ok to take responsibility for your actions and say sorry. it turns into a whole other monster once you start lying and making excuses for your behavior. With that said, at this point, both sides are saying things out of anger we all know arguing over facebook is the most rediculous thing ever. Hopefully this issue ends in a somewhat civilized, professional, PRIVATE manner. Guess this rant isn #39;t helping 😉 Here is a comment from TGA i think sums up thier defense best, although i feel like this should be resolved in private, i #39;m doing my friend a favor and making this situation known like i said i would: "You don #39;t advertise for TGA Subcool genetics for free. We have money for our own ads... we don #39;t ride other peoples coat tails... we have our own wallet. We pay the state of California nearly 1K a month for taxes... so don #39;t pretend you were doing TGA favors, we never asked and we don #39;t need them. If you ran a TGA ...From:diavoloquasarViews:1 0ratingsTime:13:57More inHowto Style

Original post:
Dabs for farmer + Next Seeds...more importantly READ DESCRIPTION - Video

Recommendation and review posted by Bethany Smith

Songlian #39;s Madness: "Raise High" #39;s Paralyzed Denouement
The end of the Raise High story has Mistress 4 in a state of paralytic madness ("her mind #39;s not right"). A satisfying congruence perhaps with the Anglo-Gothic Bronte sisters #39; (Jane Eyre), except that the condition is imposed by circumstance and confinement, not genetics: nor is chaining nor hiding her away necessary. Is it a retrospective defence (earmuffing) against the agonized scream of Meishan #39;s deathcry (a real one, not from stagescript - for which nothing can prepare)? Or is it part of an unvanquished alliance?: In the end sequence, we see Songlian cranking away a victrola wherein is embedded the remembered (but now dead) voice: a classic formula for ghostliness (the record speaks but from "somewhere else"). But the price paid for this provocation/loyalty is a severe one: whether or not clinically so, Songlian is henceforth TREATED as insane (why else try to speak with another #39;s (a dead another #39;s) voice? From what has preceded, we should not be surprised to her the dead sing - in vengeance. But this is not vengeance, it is memory, almost childish memory. An indecisive end, but then the fate of the "House of Chen" is also, to say the least, uncertain.From:James PViews:0 0ratingsTime:06:10More inEducation

Read more from the original source:
Songlian's Madness: "Raise High" 's Paralyzed Denouement - Video

Recommendation and review posted by Bethany Smith

Lies-Finchel Story Ep 31
---In the car with Quinn, Brittany and Santana--- Santana:So what did you want to tell us? Quinn:Last night, well around two this morning Finn was screaming "No!" and "Please" I love you!" and "Don #39;t Leave me!" and then he woke up sweating, panting and tears streaming down his face. Santana:*laugh* Quinn:*chuckles*What? Brittany:I don #39;t get it. Santana:So he was just screaming and then woke up crying? Quinn:Yeah. I don #39;t get it. But something else happened last night just before he took Rachel home. Brittany:What did he do? Quinn:Rachel asked him who his social worker was and just before I answered he told me he had to go so I just left it. Santana:Maybe she was asking about something else. Quinn:You think? Brittany:Totally. Quinn:If you say so.*pulls up at school* All:*get out* ---Bell Rings--- Sam:*walks over*Hey.*kisses Quinn, sticks his arm out*May I escort my lady to her class. Quinn:You may. Quam:*walk away* Brittana:*walk to class* ---After school--- ---In Glee--- Everyone:*talking* Finchel:*making out* Mr Schue:*walks in*Finn, Rachel! Finchel:*stop and listen* Mr Schue:Okay, so does anyone have any songs they would like to sing? Rachel:I would. Mr Schue:Okay.*sits down* Rachel:Do I really have to say who this is for?*winks at Finn* *music starts* Does he tell he love you, When you least expect it? Does he flutter you heart, When he kisses your neck? No scientist, Or Biology, It #39;s obvious, When he #39;s holding me, It #39;s only natural, That I #39;m so effected. And my heart ...From:finchellover16Views:3 1ratingsTime:04:06More inEntertainment

The rest is here:
Lies-Finchel Story Ep 31 - Video

Recommendation and review posted by Bethany Smith

ATLANTA--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today summarized ADCETRIS (brentuximab vedotin) and CD30 expression data in non-Hodgkin lymphomas and other malignancies from multiple presentations at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. Highlights include encouraging interim data from a phase II clinical trial of ADCETRIS in non-Hodgkin lymphoma and long-term follow up from a pivotal clinical trial of ADCETRIS in relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). In addition, investigators presented data describing the expression of CD30 in DLBCL and case studies on ADCETRIS in patients with systemic mastocytosis. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30.

This collection of data from both corporate studies as well as investigator research into CD30 and the clinical role of ADCETRIS in non-Hodgkin lymphomas add to a growing body of evidence that ADCETRIS has potential in a broad array of CD30-positive malignancies, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. The numerous data sets at ASH also reinforce our development strategy for the program and overall vision for ADCETRIS in the treatment of patients with significant unmet medical needs.

A Phase II Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas (Abstract #2746)

In an ongoing phase II clinical trial, patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas have been enrolled, including DLBCL and several other non-Hodgkin lymphoma subtypes. The trial is designed to assess the antitumor activity, duration of response and safety profile of ADCETRIS in these patients. At the time of data analysis, 73 patients had been enrolled, including 44 with B-cell lymphoma and 29 with T-cell lymphoma. The median number of prior systemic therapies in both lymphoma classifications was two. Key findings include:

ADCETRIS is not approved for the treatment of the non-Hodgkin lymphoma subtypes described in this presentation.

Long-term Remissions Observed in an Ongoing Phase II Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (Abstract #2745)

A pivotal, single-arm clinical trial was conducted in 58 relapsed or refractory sALCL patients to assess efficacy and safety of single-agent ADCETRIS. In addition, the trial was designed to determine duration of response, progression-free survival and overall survival. Enrolled patients had received a median of two prior chemotherapy regimens.

Data highlights from long-term patient follow up in the pivotal trial were:

CD30 Expression in Diffuse Large B-Cell Lymphoma (Abstract #1558) and CD30 Expression in DLBCL and Its Relation to Important Clinical and Biological Disease Features (Abstract #1592)

Go here to read the rest:
Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data in CD30-Positive Non-Hodgkin Lymphomas and Other ...

Recommendation and review posted by Bethany Smith

ATLANTA--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today announced results from a phase I clinical trial of ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL). The data were presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30. ADCETRIS is not currently approved for use in the front-line treatment of MTCL.

In the phase I trial, newly diagnosed patients received six cycles of ADCETRIS every three weeks in combination with cyclophosphamide, doxorubicin and prednisone (CHP). This regimen removes vincristine (Oncovin) from CHOP, the standard treatment in this setting. Patients who achieved at least a partial remission after completing six cycles of combination therapy were eligible to receive continued single-agent ADCETRIS for up to ten additional 3-week cycles. The primary endpoints of the trial included defining maximum tolerated dose of ADCETRIS in combination with CHP and evaluating safety. The secondary endpoints were investigator assessment of response, progression-free survival and overall survival.

After completing combination therapy, 26 of 26 patients (100 percent) treated with ADCETRIS plus CHP had an objective response, including 23 patients (88 percent) with a complete remission. All 23 patients who achieved a complete remission demonstrated normalized glucose uptake by PET (positron emission tomography) evaluation.

The standard front-line regimen for patients with mature T-cell lymphomas is a combination chemotherapy regimen, CHOP, that has demonstrated complete remission rates of 39 to 53 percent, with a 5-year overall survival rate of less than 50 percent, said Michelle Fanale, M.D., Associate Professor in the Department of Lymphoma/Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. There is significant need to advance the treatment paradigm for newly diagnosed patients with these aggressive types of lymphoma. Data from this trial support further evaluation of ADCETRIS in the front-line treatment of patients with mature T-cell lymphomas.

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy as Front-line Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas (Abstract #60)

Data were reported from 26 previously untreated patients who received the combination regimen of ADCETRIS plus CHP. Nineteen patients had sALCL, and seven patients had a diagnosis of another mature T- or NK-cell lymphoma. The median age of patients was 56 years. Key findings, which were highlighted in an oral presentation by Dr. Fanale, include:

These data provide strong rationale for our planned phase III clinical trial to evaluate ADCETRIS plus CHP compared to CHOP in front-line patients with mature T-cell lymphomas, said Clay B. Siegall, Ph.D., President and Chief Executive Officer at Seattle Genetics. We are encouraged by the potential to introduce ADCETRIS into a novel regimen for these patients, with a goal of redefining front-line therapy from the standard therapeutic approach that has not seen an advance in decades.

A phase III clinical trial of ADCETRIS in CD30-positive MTCL patients is planned to compare progression-free survival in patients receiving ADCETRIS in combination with CHP (A+CHP) to patients receiving CHOP alone. The trial is expected to begin by late 2012 or early 2013.

About ADCETRIS

Read more here:
Seattle Genetics Reports Data from Phase I Trial of ADCETRIS® (Brentuximab Vedotin) in Front-line Mature T-Cell ...

Recommendation and review posted by Bethany Smith

NATHAN KLEIN- FIRST MAN GENE THERAPY FOR PARKINSONS DISEASE
FIRST MAN TO RECIEVE GROUND BREAKING GENE THERAPY FOR PARKINSONS DISEASEFrom:venture1webViews:12 0ratingsTime:03:27More inScience Technology

Visit link:
NATHAN KLEIN- FIRST MAN GENE THERAPY FOR PARKINSONS DISEASE - Video

Recommendation and review posted by Bethany Smith

ATLANTA, Dec.8, 2012 /PRNewswire-USNewswire/ -- The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

CLL is a blood cancer that causes abnormal white blood cells called lymphocytes to accumulate in the blood, bone marrow, and in the lymph nodes or other organs, causing these organs to enlarge. Approximately 15,000 Americans are diagnosed with CLL every year; nearly 70 percent of those affected are 65 and older.[1], [2]For some patients with slower growing disease, physicians employ "watch and wait" strategies to minimize unnecessary treatment. However, patients with high-risk features such as rapidly progressing disease require prompt treatment to manage symptoms and reduce organ damage.

Ibrutinib is a specialized anti-cancer therapy that targets the Bruton's tyrosine kinase (BTK, an enzyme important in the development of CLL). As an inhibitor of BTK, ibrutinib selectively targets leukemia cells, promoting their death and preventing them from growing while leaving normal cells unharmed. Studies suggest this design allows the drug to more effectively treat the disease, with encouraging early results in harder-to-treat patient groups such as elderly untreated patients and those whose disease has become resistant to other therapies or those who have experienced disease recurrence after receiving other therapies. Two studies will present efficacy and safety results testing the compound alone and in combination with other currently used therapies for CLL.

"The evidence collected to date on ibrutinib demonstrates that it may have the potential to improve long-term prognosis for patients who are not sensitive to standard treatment," said Claire E. Dearden, MD, moderator of the press conference, Consultant Hematologist and Head of the CLL Unit at The Royal Marsden NHS Foundation Trust in London. "Equally important, the exciting efficacy and safety data that we are seeing for this drug in these studies underscore the significant progress we are making in our quest to better understand and attack the specific cellular targets responsible for CLL, particularly in these vulnerable patient populations."

This press conference will take place on Saturday, December 8, at 8:00 a.m. EST.

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and is Tolerable in Treatment Naive (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in Phase Ib/II Study [Abstract 189]

New research demonstrates that a novel investigational therapeutic agent called ibrutinib may be an effective and safe targeted treatment option for previously untreated, hard-to-treat, and relapsed patients with chronic lymphocytic leukemia (CLL).

Primary treatment for CLL includes a combined chemotherapy-based regimen with fludarabine and cyclophosphamide, along with the immune therapy rituximab. While rituximab is effective, it is generally not well tolerated among elderly patients. Treatment with this drug also compromises the immune system by attacking both cancerous and normal cells, putting patients at risk for a range of infections and increasing their risk of developing treatment-related acute myeloid leukemia.

To understand if ibrutinib may be effective for elderly CLL patients and to identify which patients might benefit most from the drug, researchers enrolled 116 CLL patient participants in several treatment cohorts: patients who were never treated (the treatment-naive group), those who had received two or more prior therapies (the relapsed/refractory group), those who had relapsed within two years of treatment (the high-risk group), and those over age 65. Two oral dosing regimens (420 mg or 840 mg daily) of ibrutinib were used. The primary goal of the study was to determine the safety of the low and high doses; secondary objectives included efficacy, measures of the intensity of the drug's effect in the body, and the long-term safety of administering this therapy continuously until relapse.

The study found that response to therapy was high across the cohorts, with largely manageable toxicities. Previously untreated elderly patients responded best to the agent, with 71 percent experiencing a complete or partial response at either treatment dose. The same response was observed in 67 percent of the relapsed patients and 50 percent of the high-risk patient cohort. After 22 months of follow-up, the disease had not progressed in 96 percent of previously untreated patients and 76 percent of relapsed and high-risk patients.

Go here to see the original:
New Investigational Agent Targets Gene Signaling Pathways to Improve Therapeutic Response for Patients with Chronic ...

Recommendation and review posted by Bethany Smith

Islands at Risk Genetic Engineering in Hawaii GMO Part 1
From:DocumentaireOnlineViews:7 1ratingsTime:09:30More inPeople Blogs

More here:
Islands at Risk Genetic Engineering in Hawaii GMO Part 1 - Video

Recommendation and review posted by Bethany Smith

Islands at Risk Genetic Engineering in Hawaii GMO Part 2
From:DocumentaireOnlineViews:0 0ratingsTime:09:24More inPeople Blogs

Read the original here:
Islands at Risk Genetic Engineering in Hawaii GMO Part 2 - Video

Recommendation and review posted by Bethany Smith

Islands at Risk Genetic Engineering in Hawaii GMO Part 3
From:DocumentaireOnlineViews:0 0ratingsTime:09:41More inPeople Blogs

Originally posted here:
Islands at Risk Genetic Engineering in Hawaii GMO Part 3 - Video

Recommendation and review posted by Bethany Smith

Invitation Stop Monsantoizing our Food and Agriculture
Workshop on: MONSANTO, A THREAT TO HEALTH, ENVIRONMENT HUMAN RIGHTS Sunday, 9th December 2012 starting at 10 am Venue: Seminar Hall No 1, ICSSR Complex, Panjab University Campus, Chandigarh All are invited. Building People #39;s resistance to the Poisoning of our Food Future of Food in the Era of proprietary seed technologies is under severe threat. Monsanto is a dangerous Agro-Chemical, Seed and Genetic Engineering Giant. Monsanto is entering Punjab on the invitation of Government of Punjab. Monsanto is invited here to establish Research Centre in Punjab Monsanto #39;s markets expanding with taxpayers #39; funds in recent past Remember the drubbing that they got from KRRS in Karnataka Monsanto is known for its anti-Farmer, anti-People, anti-Nature products and operations world-over. It has not hesitated to use unethical and illegal bribing of decision-makers to get approvals for their products elsewhere. It has chased farmers and other for so-called royalties upto the import shores in Europe, from developing countries. It has sued and jailed farmers in the name of patent infringement. It is a profit-hungry corporation that reportedly had set as its objective control over all food grown. Monsanto controls most of the GM crop cultivation in the world -- this is a technology that is known to have health, environmental and trade impacts all over the world. Monsanto is our modern-day East India Company, bringing food and agricultural imperialism knocking at our doors. Let us oppose ...From:Aawaaz dotnetViews:0 0ratingsTime:00:36More inNonprofits Activism

See the rest here:
Invitation Stop Monsantoizing our Food and Agriculture - Video

Recommendation and review posted by Bethany Smith

Exclusive Genetics at #FanFest w/Billy Jaynes (Matt Jane)
From:matthew rappaportViews:0 2ratingsTime:16:18More inEntertainment

View post:
Exclusive Genetics at #FanFest w/Billy Jaynes (Matt

Recommendation and review posted by Bethany Smith

Single Cardiomyocyte beating
Beating cardiomyocyte generated from human iPS after monolayer dissociation. Day 29 of differentiation / Day 12 after monolayer dissociation. Laboratory of Genetics and Molecular CardiologyFrom:Diogo G BiagiViews:0 0ratingsTime:00:07More inPeople Blogs

The rest is here:
Single Cardiomyocyte beating - Video

Recommendation and review posted by Bethany Smith

VNT Genetics 3
descriptionFrom:abby osmunViews:1 0ratingsTime:01:22More inScience Technology

Link:
VNT Genetics 3 - Video

Recommendation and review posted by Bethany Smith

Bacterial Genetics
Foundations of Bacterial GeneticsFrom:DocterindotcomViews:4 0ratingsTime:11:04More inEducation

Go here to see the original:
Bacterial Genetics - Video

Recommendation and review posted by Bethany Smith

Treeing Walker Coonhound doing his thing
My rescued Walker Coonhound Cooper doing what he was bred for, although this is with a squirrel. Really fun to watch the instincts and genetics kick in from time to time.From:mcfarl58Views:0 0ratingsTime:00:46More inPeople Blogs

See the original post here:
Treeing Walker Coonhound doing his thing - Video

Recommendation and review posted by Bethany Smith

Hulk Trailer 2003
Bruce Banner, a genetics researcher with a tragic past, suffers an accident that causes him to transform into a raging green monster when he gets angry.From:Benjamin RodriguezViews:0 0ratingsTime:02:30More inPeople Blogs

Go here to read the rest:
Hulk Trailer 2003 - Video

Recommendation and review posted by Bethany Smith

Seeing the Unseen in Cell Machinery by Label-free Spectroscopic Imaging
webinar Elsevier Dr. Ji-Xin Cheng Associate Professor, Weldon School of Biomedical Engineering Moderator: Kaia Motter Publisher, Genetics IIFrom:TheEvgenkenViews:1 0ratingsTime:58:04More inScience Technology

See more here:
Seeing the Unseen in Cell Machinery by Label-free Spectroscopic Imaging - Video

Recommendation and review posted by Bethany Smith

Genetics with a Concentration of Clones
~School Science Project~ Featuring Naila, Aleeah, and Joan.From:MsJoan1999Views:0 0ratingsTime:07:22More inMusic

Visit link:
Genetics with a Concentration of Clones - Video

Recommendation and review posted by Bethany Smith

SALT LAKE CITY, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) announced today that a presentation entitled "Homologous recombination deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer (BC)," was presented on Friday, December 7, 2012 at the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas. The study demonstrates that Myriad's HRD test strongly predicts which primary tumors will respond to platinum-based combination therapy in patients with triple-negative breast cancer.

Triple-negative breast cancer describes breast tumors that lack estrogen receptor, progesterone receptor and HER2. This type of breast cancer tends to be more aggressive than other subtypes of breast cancer and has not been amenable to targeted therapies. The platinum class of drugs kill tumors by causing DNA damage inside the tumor and may be particularly effective against tumors that have lost their ability to repair DNA.

Researchers at Stanford University School of Medicine and Myriad Genetics studied the pathologic response of tumors in patients with triple-negative breast cancer to a carboplatin-based therapy and showed that the HRD test can significantly predict patient response to such therapy. 70% of patients with an HRD score >=10 responded to the carboplatin treatment, compared to only 20% of patients with an HRD score < 10 (p=0.0001). Using the HRD test instead of BRCA status identified more than 3 times as many patients as likely responders. The HRD test may prove to be a very important tool in guiding the treatment of patients with triple-negative breast cancer.

"DNA repair deficiency is believed to be a property of a significant number of triple-negative breast tumors," said Dr. James Ford of Stanford University School of Medicine, the senior author of the study. "The HRD score has enabled us to effectively identify the majority of responders with high accuracy."

Many breast tumors are believed to be deficient in DNA repair capacity. Myriad's HRD test is designed to predict patient response to DNA damaging agents such as platinum drugs and PARP inhibitors that may be more effective against these subsets of breast cancer. With further research, the use of the HRD test may become an important tool to guide treatment decisions in all breast cancer patients.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's genetic risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com

Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-G

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995,including statements relating to the ability of the HRD test to predict which primary tumors will respond to platinum-based combination therapy in patients with triple-negative breast cancer; whether the HRD test will become a important tool to guide the treatment of patients with triple-negative breast cancer and in all breast cancer patients; and the Company's strategic directives under the caption "About Myriad Genetics". These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and companion diagnostic services may decline or will not continue to increase at historical rates; the risk that we may be unable to expand into new markets outside of the United States; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and companion diagnostic services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and companion diagnostic services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and companion diagnostic services and any future products are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with manufacturing our products or operating our laboratory testing facilities; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of healthcare payment systems; risks related to our ability to obtain new corporate collaborations and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we acquire; the development of competing tests and services; the risk that we or our licensors may be unable to protect the proprietary technologies underlying our tests; the risk of patent-infringement and invalidity claims or challenges of our patents; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Read the original post:
Myriad Genetics' HRD Test Predicts Response to Platinum Therapy in Triple-Negative Breast Cancer

Recommendation and review posted by Bethany Smith

Gene Therapy (Advanced Biotechnology Project)
james73394 #39;s shared video file.From:James ReisViews:0 0ratingsTime:03:01More inScience Technology

Read the rest here:
Gene Therapy (Advanced Biotechnology Project) - Video

Recommendation and review posted by Bethany Smith

Spinal cord injury L1 treadmill training
Spinal cord injury 8 months post. Training side steps on treadmill.From:beatspinalcordinjuryViews:0 0ratingsTime:01:13More inPeople Blogs

Here is the original post:
Spinal cord injury L1 treadmill training - Video

Recommendation and review posted by sam

Spinal cord injury,weight lifting,Bench Press,160 kg / 352,5 lbs with a spotter
Arnar Helgi Lrusson sci 2002 T2/3 complete This video is since 2012 visit my website http://www.wix.comFrom:Arnar lrussonViews:0 0ratingsTime:01:38More inPeople Blogs

View original post here:
Spinal cord injury,weight lifting,Bench Press,160 kg / 352,5 lbs with a spotter - Video

Recommendation and review posted by sam

Shawn Chavez, PhD, talks about research on selecting healthy embryos for IVF
During in-vitro fertilization (IVF), physicians much choose among many embryos to pick the ones that are most likely to produce a successful pregnancy and health child. Shawn Chavez, PhD, a researcher at the Stanford Institute for Stem Cell Biology and Regenerative Medicine, talks about an automated time-lapse recording system that can accurately detect which embryos are healthiest. She discusses new research showing that a parameter called "fragmentation" is important.From:institutesofmedicineViews:3 0ratingsTime:02:05More inEducation

Originally posted here:
Shawn Chavez, PhD, talks about research on selecting healthy embryos for IVF - Video

Recommendation and review posted by sam